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Abstract 
This paper discusses the possible ways to analyse the data, adopting a matrix notation, so often 
used in Bioassays. The paper also reviews the Multistage Models (MM). The MM class of 
models is applied for extrapolation, to the region of Low-Dose. The effect of covariates in 
experimental carcinogenesis is introduced and the relative efficiency is evaluated. Certainly 
the discussed case was refereed to uncorrelated covariates and therefore an open problem 
might be the multicollinear predictive covariates.Various nonlinear models are discussed, 
giving more emphasis on the Michaelis-Menten and the Fisher’s information for them is 
discussed. 
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1. Introduction 
This paper reviews the Multistage Models (MM) and provides some nonlinear models 
adopting to Cancer Bioassays. The MM class of models is applied for extrapolation, 
to the region of Low-Dose, Kitsos (1997) while the general prediction problem has 
been discussed under a different approach by Kitsos (1993), with some applications to 
carcinogenesis. The effect of covariate omissions in experimental carcinogenesis is 
introduced and the relative efficiency is evaluated. In Appendix the Michalis-Menten 
model and some extensions on it are discussed. A number of graphs of various curves 
adopting in bioassays are presented in Appendix B, while the Fisher’s Information for 
some models is evaluated in Section 5. 
2. Descriptive Summary Tables and Analysis 
A common way of presenting summary data, in all the of statistical problems, and 
therefore in Cancer Epidemiological studies, is through the use of a data matrix, to 
                                                 
1 Died in a car accident on March 17, 2009. 
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create a Table, to group the data, in Kendal’s suggestion. However, a formal 
construction of a Table, must be defined in such a way so that to model the logical 
design underlying of the appropriate statistical data set of a epidemiological study or 
Bioassay. A summary statistic can be eventually viewed as a mathematical function. 
The so called “dependent” variable of the function is a numerical variable, which is 
referred to as the summary variable (elsewhere called summary attribute, and analysis 
variable, or response variable). A summary variable is defined by a name and a type 
(e.g., real, integer, nonnegative real, nonnegative integer). The “independent” 
variables are nominal or range variables, which are referred to as category attributes 
(elsewhere called categorical variables and classification variables, or input 
variables). 
In principle a category attribute in Biological studies and especial in Cancer 
Bioassays is defined by a name and a domain. Usually the domain consists from a 
few values (usually called “codes”), that is the ordinal number of the domain is a 
small positive integer number. 
For example, the categorical variable sex is a two valued category attribute, which is 
often used to all epidemiological studies, and “acts as covariate” to some of these. 
Same treatment needs the categorical variable Cancer (“yes” or “no”), while the value 
“yes” needs further investigation (through another categorical value) concerning the 
“type” of Cancer. 
So if we consider the set C={C1,.....,Cr} of all category attributes in a given 
population Ω we can consider that there is assigning a mapping (or set function)  μj 
from the domain of Cj  to the power set of Ω , j=1,…..,r. Given a category value cj, 
then the values of μj (cj) denotes the set of units of observation matching the condition 
Cj  = cj, and is called the category associated with the category value cj.  
Two main assumptions has to be considered, even though there are not stated in 
Cancer Bioassays problems: 
• Assumption 1. Partitioning attributes. 
Each unit of observation in Ω falls into at most one elementary category.  
•  Assumption 2. Data additivity.  
The summary variable X provides additive total information.  
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Assumption 1 simply declares that elementary categories are mutually disjoint and 
cover Ω. In other words, the set of category attributes C acts as a classification 
scheme for the units of observation in Ω. This assumption is usually testing by a 
n m×  contingency table and the appropriate X2 test. The 2x2 is the most well known 
and is sometimes linked with the logit model, Kitsos (2007). Assumption 2 declares 
that the total information for the variable X is the sum of the information provided by 
each observation of X. In principle, by “information” the defined by Fisher 
information is considered. The augmentation of the data provides “more information” 
additively, in the sense that the total information is the sum of the information added 
by the n observations. This certainly needs the independence assumption which is 
always there, somehow considered by the experimentalist, although not always true. 
But even is such cases the likelihood function can be evaluated for all the 
observations, by “pretending” that Ford and Silvey (1980), are independed, Kitsos 
(1992). 
It is widely accepted that the first stage statistical analysis, especially to Biological 
data analysis is based on a compact “table form” of the data.  
Considering a statistical analysis, which contains multiple summary tables over the 
same population, the following definition is given. 
Definition 2.1. Two or more summary tables 1,..., sT T  are homogeneous, if they 
contain data on the same summary variable X for the same population Ω, but use 
different classification schemes . 
The collection of the Ti’s is referred to as a polyptych (diptych for 3s = , triptych for  
3s = ) of summary tables on X in Ω.  
A problem raised by the management/manipulation of a statistical analysis for the 
collected data, is when containing a polyptych of summary tables. In such a case the 
data integration, which consists in viewing the tables of a polyptych as “projections” 
of a higher-dimensional summary table, called the universal table. As an example it is 
rather difficult the EU data set from Cancer projected to country XX to provide the 
exact summary statistics for this particular country. 
For a universal-scheme interface to be practical, the polyptych under examination has 
to be consistent. That means that there exist universal tables, that is, a summary table 
with classification scheme U, whose “projection” on the Ri’s return the tables of the 
polyptych. This needs a certain organization of the data sets, which is not so happen 
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in practice, although various research centers on Cancer attempts so. In order to state 
the notions of a universal table and consistency precisely, we  introduce two notions: 
that of a marginal of a summary table and that of a universal category relation. 
Definition 2.2. A universal category relation is a category relation over the universal 
classification scheme U such that its projections onto the Ri’s restore the category 
relations Ri’s of the tables of the polyptych. 
An interesting case occur whenever two or more category attributes refer to a 
common, but not identical categorization criterion, and therefore is more or less 
tightly connected. This is a weak point of the statistical analysis of the Bioassay. That 
is we would recommend a pilot study before any statistical data analysis. Based on 
this knowledge, it is asked to take the proper subset U of the natural join U*, as a 
universal category relation, obtained by removing from U* the part (tuple) that can be 
inconsistent with the semantic constrains known to the statistical and medical 
analysts.  
Notice that a tuple in U may refer to an empty category (accidentally empty 
category); such a tuple is called a dummy tuple. This distinction between structurally 
empty categories and accidentally empty categories which often occurs in the analysis 
of statistical data has to be reminded.         
Definition 2.3. A universal table for a polyptych of summary tables is a summary 
table with classification scheme U and category relation U such that its marginal over 
the Ci’s coincide with the summary tables of the polyptych  
Definition 2.4. A polyptych is consistent if it admits a universal table. 
Due to assumptions 1 and 2, we eventually represent, in any Bioassay the universal 
tables as solutions of a linear constraint system.        
A typical case in which a polyptych of summary table turns out to be consistent 
occurs when these come from a single data source. When summary tables are taken 
from distinct data sources, it is very improbable that the requirement of consistency 
will be fulfilled-inconsistency.  
These points might be not so widely considered by an experimentalist, but the 
statistical techniques are strength with such considerations. 
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3. The covariates as extra categories 
In most bioassays and at the experimental carcinogenesis as well, the target is to 
compare two different therapies/factors, so according to Section 1 it is 1 2{ , }C C C= , 
or to evaluate the prognostic factors. But in principle, the population under study Ω, is 
rather heterogeneous with respect to prognosis, it is asked to adjust the covariate 
effect describing the above mentioned heterogeneity, Cox and Snell (1989). Let x1 be 
the factor of interest and x2 the covariate and β1, β2 be the corresponding regression 
parameters. Fitting the full model with link function Link, McCullagh and Nedler 
(1989),  
1
1 2 0 1 1 2 2( | , ) Link ( )E Y x x x xβ β β−= + + ,  (3.1) 
 while the restricted model with estimate *1β  is 
1 * *
1 0 1 1( | ) Link ( )E Y x xβ β−= + .  (3.2) 
Notice that the models (3.1) and (3.2) although nonlinear, are intrinsic linear. The 
corresponding variances to models (3.1) and (3.2) are: 
2 2
1 2 .12 1 .1var( | , ) ,   var( | )Y YY x x Y xσ σ= =   (3.3) 
Therefore the (relative) efficiency of 1ˆβ  to *1ˆβ can be defined as 
( ) 2 2* .12 121 1 2 2
.1 2.1
1ˆ ˆeff ,
1
Y
Y Y
σ ρβ β σ ρ
−= = − ,  (3.4) 
with ρ12 = Corr(x1, x2) and ρΥ2.1 is the effect of x2 on Y. From (3.4) is easy to see that  
( ) 2.1 12*1 1 12 2.1
12 2.1
1, if | | | |
ˆ ˆeff , 1, if
1, if
Y
Y
Y
ρ ρ
β β ρ ρ
ρ ρ
=⎧⎪= < >⎨⎪> <⎩
.  (3.5) 
In principle, interest is concentrated on a randomized treatment effect, i.e. ρ12=0. That 
is emphasis is given in adjustment as eventually eff( *1 1ˆ ˆ,β β )≥1. The question if 
2 0β = , which is actually a statistical null hypothesis, versus 2 0β ≠  is crucial on 
misspecification by omitting or including x2. Indeed: if x2 is adjusted for, the assumed 
correct model (3.1) is fitted provided 2 0β ≠ . If 2 0β =  this leads to overspecification 
of the model. If x2 is not included, the (3.2) model is correct if 2 0β =  while if 2 0β ≠  
the model (3.2) is underspecified. 
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If the link function is the logistic function, which remains invariant under certain 
transformation, Kitsos (2007a),  the models (3.1) and (3.2) are reduced to 
1.12
0 1 1 2 2
1.12
log
1
P x x
P
β β β= + +− ,  (3.6) 
* *1.1
0 1 1
1.1
log
1
P x
P
β β= +− ,  (3.7) 
with 1,2 1 2[ 1| , ]P P Y x x= =  and 1,1 1[ 1| ]P P Y x= = . In case that *1 1β β=  the plane (3.6) 
and the line (3.7) are parallel (Figure 1). The statistical implementation of this is 
equivalent that the RR for 1x  estimated either from (3.6) and (3.7) are equal as 
*
1 1RR e eβ β= = , otherwise the evaluated Relative Risk are non equal and is a matter of 
investigation. Notice that in both cases (3.6) and (3.7 are linear). If a second order 
model was consider, at least fir (3.7) the test for the curvature is really a necessity. 
 
 
 
 
 
 
 
 
 
 
Figure 1. (3.6) plane and (3.7) line. 
Notice that for the logistic model the curvature 1/ ( )Link ⋅ , is a convex leading 
function, to a downward bias of *1β  i.e. *1 1ˆlim | | | |β β< , therefore the bias tends to zero 
only when 1 0β = . Relative Risk to be equal to unit, i.e. RR 1= .  
There is a similarity of the logistic and the Cox model, Prentice and Kalbfleisch 
(1979), Schumacher et al. (1987), Legakos and Schoenfeld (1984), while the behavior 
of the variances of the adjusted and unadjusted estimators need, we think, more 
1x  2x
y  
(3.7)  
(3.6)
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investigation in this particular problem. We emphasize that the *0var( )β ) and 
*
1var( )β  in (3.7) can be reduced if a D-optimal or Ds-optimal design approach is 
adopted, Ford et al (1989), Kitsos (2007a). 
4. Low-Dose models 
There are different statistical models to describe a process by which a normal cell 
becomes malignant through, at least one, transformation. When the malignancy is 
referred to a tumor we are referred to cancer. Then, the interest is focused on the 
“growth rate” of affected tissues as malignant tumors are capable of floating away 
and forming new malignant growths in other sites. Humans are certainly exposure to 
carcinogens, which is accepted for two main reasons:  
• there  are no reliable estimates for “safe doses” and 
• the epidemiological methods are insensitive to small increase in cancer. 
In quantitative toxicology the following definitions are adopted. 
Definition 4.1. By “dose” we define the amount of chemical or energy in a 
radiological situation administered to or reviewed by exposed subject. 
Definition 4.2. By “effect” we define an action as a result of a stimulus received 
through a receptor. 
Definition 4.3. By “response” we mean any detectable change (and is assumed 
approached through a statistical model). 
A number of extra definitions on the introduced term “dose” are considered. We 
briefly referred to them. 
 A “safe dose” it is assumed that will not increase the current cancer incidence rate by 
more than an “acceptable” low risk level, see the early work the Hartley and Sielken 
(1977). The “virtually safe dose” (VSD) was based on confidence intervals and it was 
rather mechanistic (Grump et al. (1977), Armitage (1982)). The upper confidence 
limit for the proportion of tumours was calculated and the dose-response curve was 
extrapolated towards zero.  
Certainly one of the problems in the cancer risk assessment is the extrapolation from 
the experimental results to human Zapponi et al (1989). There are also different scale 
parameters and are discussed in comparisons of LD10≡L.1, Brown and Howel (1983). 
These parameters are based on different species and a given set of chemicals. That is 
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still interest is focused on low dose, which is equivalent to calculate the percentile Lp, 
p∈(0,1) for “small” p, 0 < p ≤ 0.1, Kitsos (1997). 
Although different terminology is adopted for the percentile point, like MTD, 
maximum tolerance dose, TD, tumorigenic dose, ED, estimated dose, LD, lethal dose 
the point remains the same: adopt that model which will provide the best downwards 
extrapolation to pL , as it has no meaning to perform experiments below an unknown 
level of dose.  
The crucial issue when fitting a model is prediction. The effect of covariates has to be 
considered, through the, assumed correct, model. The low-dose effects in a risk 
assessment have also to be within the study.   
Different nonlinear models have been developed and applied under the name 
multistage models (MM). The class of MM has been mainly applied for the analysis 
of a large number of epidemiological data, Armitage (1985).The crucial issue when 
fitting a model from MM class is prediction. That is extrapolation downwards in the 
neighbourhood of zero, while prediction in statistics is rather related with a forward 
extrapolation. This is an interesting exception in the statistical General Model theory, 
where prediction is relating, mainly, in a forward extrapolation and in a lesser extend 
to the within the domain values. 
There is a rather empirical approach to these models by toxicologists and 
environmentalists, without a reference to an explicit dose-response model, as tumour 
incidence data is titled to a prescribed dose-response relationship. These experimental 
approaches are still valuable and might provie interest results, Angelopoulou et al. 
(2008a, 2008b). 
The dose-response curve, ( )F ⋅  say, is a result of a binary response problem, recall 
Section 1, i.e. there are only two categories C1 and C2, see Kitsos (1998) for details. 
From the statistical point of view F(x) is the cumulative distribution function, for the 
underlying probability model, describing the phenomenon. The notation x is referred 
to the dose level.  However, due to a number of factors, including the temporal 
variability of animal population characteristics and the difficulty in identifying a 
specific animal breed, this dose-response curve is rather problematic to biologists and 
toxicologists. Moreover, F(x) is rather an assumed approximation, than a known 
deterministic mechanism for the phenomenon which describes. Therefore it needs an 
estimation and we would strongly recommend a Kolmogorov-Smirnov test.  
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When it is assumed that cancer is the result of a single event (or "hit") in a single cell, 
the one parameter exponential model 
( ) 1 exp( ),   0F x xθ θ= − − > ,  (4.1) 
it is, known as one-hit model. 
When a fixed number, say k, of (identical) "hits" occur in a tissue the multi-hit model 
is assumed to describe the phenomenon and the corresponding F(x) is approximated 
by the assumed correct model 
1
0
1( )
( 1)!
x k uF x u e du
k
− −= − ∫ .  (4.2) 
When a sup linear relationship is assumed the one hit model is transformed to 
Weibull model with shape parameter, s say 
( )( ) 1 .
sxF x e θ−= −  
The maximum likelihood estimation (MLE) for the parameters ( , )s θ , both assumed 
unknown, of the Weibull distribution  is ( , )L L s θ=  and the log-likelihood ( , )l l s θ= . 
Recall that the Weibull does not belong to the exponential family of models. The first 
derivatives are needed to evaluate the corresponding score functions  
1 ,s si
l sdU s xθ θθ θ
−∂= = −∂ ∑   (4.3) 
1/
* .
s
s
i
x
t
θ ⎛ ⎞= ⎜ ⎟⎜ ⎟⎝ ⎠∑   (4.4) 
When s is given, the MLE θ* of θ can be found explicitly by solving 0Uθ =  as 
The second derivatives of the log-likelihood l are 
2
1 2
2 2 ( 1) ,
s s s s
i i
l sd sdI s t s s tθθ θ θθ θ θ θ
− −∂ ∂ ⎛ ⎞= = − = − − −⎜ ⎟∂ ∂ ⎝ ⎠∑ ∑  
( )2 1 11 log log ,s s s ss i i il dI s t s t tsθ θ θ θθ θ − −
∂= = − + −∂ ∂ ∑ ∑  
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( )2 22 2 log .s sss i il dI t ts s θ θ
∂= = − − ⎡ ⎤⎣ ⎦∂ ∑  
Therefore Fisher’s information matrix can be evaluated, as ijI I= , i,j = 1,2 with 
11 22 12 21,  ,  ss sI I I I I I Iθθ θ= = = =  . 
When it is assumed that the susceptible cell can be transformed through k distinct 
stages in order to be a malignant one the multistage model of Armitage-Doll (1954) 
described the phenomenon. The main assumption was that the transformation rate 
from each stage to the next on is linear. Eventually the cdf of developing cancer from 
exposure to a dose x, within a fixed time period, is given by 
0 1( ) 1 exp[ ( ... )]
k
kF x x xθ θ ϑ= − − + + + ,  (4.5) 
where ,  0,1,...,i i kθ =  are defined through the coefficients of the linear transfor-
mations assumed between stages, Grumb et al. (1977), i.e. i i (t)ϑ ϑ= . The most usual 
model are the multistage linear model and the multistage model. Notice that model 
(4.5) developed on a completely different biological insight and not as general 
mathematical form of the previous models.  
The Logit and Probit models, Mc Cullagh and Nedler (1993), known as tolerance 
distribution models in cancer risk assessments, are also useful to toxicology and are 
included to MM class.  
In pharmacokinetics for cancer risk assessment the Michaelis-Menten metabolic 
process is usually considered when it is assumed to lead to a concentration of the 
active metabolite in the target tissue considering as function of x, see Appendix 1 for 
more details. 
The MM class is the earlier appeared, Armitage and Doll (1954), and is based on the 
assumption that a single normal cell may become fully malignant when a sequence of 
say k, irreversible heritable mutation-like changes assumed. Now, under the 
assumption that the intermediate cells are subject to a stochastic birth-death process 
for cell proliferation and cell differentiation, when 2k =  the Biologically Based 
Models (BBM) was created by Moolgavkar and his associates, see Moolgavkar and 
Venson (1979) and developed by a series of papers by Luebeck and Moolgavkar 
(1989, 1991, 1992).  
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The two families of models, the MM and BBM, are based on different hazard 
functions. Indeed if the mutation rates are very small and independent of time the 
hazard function of cancer for the Armitage–Doll model is 
1
0( ) ( ) ,   0
kt c t t cλ −= − > ,  (4.6) 
where k is the number of stages, t0 is a fixed and positive number for the growth of 
tumour. 
When interest is focused to identify etiological agents of cancer and develop the 
appropriate statistics for risk assessment of environmental agents then the most 
appropriate hazard function is the one defined by Cox (1972) as 
0( ) ( ) ( , )t t S Wλ λ β= ,  (4.7) 
with λ0(t) > 0 known as baseline hazard function, ( , )S W β  the risk function which 
relates the environmental factor W, i.e. the covariates and the vector of unknown 
parameters β . This model is known as a proportional-hazard model. 
An interesting application of the proportional-hazard models has been discussed by 
Pargament et al. (2001). He worked on religious struggle as a predictor of mortality 
among sick patients. His data set was based on 576 Baptists and Methodists, age over 
55, hospitalized in a particular hospital, and they were follow-up for two years with 
176 deaths and 152 subjects were lost to follow-up. Adopting o proportional-hazard 
model an interesting, rather social than medical analysis is presented. A well known 
technique for cancer is screening. If screening speeds-up detection that will 
eventually increase the time (known as “lead time”) from detection to death. The lead 
time for the breast cancer screening was discussed by Patz et al. (2000), Welch at al. 
(2007). 
Proportional-hazard models are mainly applied in clinical trials. In principle, in a 
clinical trial we need to know a curve for the treatment group and another one for the 
control group, due to Kaplan-Meier estimator. If the treatment is not depended on 
failure time the corresponding survival curve will fall off slowly, while if the 
treatment has no effect the two curves will statistically coincide. The above 
discussion only tries to encourage that the mathematical formulation, does not solve 
the problem, it describes it. An essential analysis is needed as the conclusions are 
rather sensitive, concerning human lives. 
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The MMB are based on a Poisson process for stage to stage. For example Moolgarkar 
and Venzon (1979) assumed a Poisson process with birth rate at i cell ( )ib t ib=  and 
death rate at i cell ( )id t id= , i.e. a homogenous birth-rate process. 
5. Nonlinear Models 
In this section we briefly discuss typical non-linear models which might provide 
response curves with no significant difference between them are, with the same 
parameter vector. But when the parameter vector is based on different values the 
same non-linear might appear close to a line. That is why we review these models, we 
evaluated their graphs in Appendix B were these graphs, within an MS Excel 
environment, can easily provide the curve by changing the initial guesses for the 
estimators. For a number of these models the Fisher’s information matrix is evaluated 
as 2( ) ( ) ( )Ti f fθ σ == ∇ ∇  for an observation. In other cases, the partial derivatives are 
evaluated so that to form ( )i θ , see Kitsos (2007b). 
MODEL   NAME 
1. 20 1( , ) exp( )
u
Gf u e
θθ θ θ=  : Gompetz model. 
2. 30 1 2( , ) exp( )Jf u u
θθ θ θ θ= +  : Janoscheck model. 
3. 20 1( , ) (1 )
u
Lf u e
θθ θ θ= +  : Logistic model. 
4. 2 30 1( , ) [ ]
u
Bf u e
θθ θ θ= +  : Bertalanffy model. 
5. ( )tanh 0 1 2 3( , ) tanh ( )f u uθ θ θ θ θ= + −  : tahn-model. 
6. ( )03- tanh 1 22( , ) 1 arctan ( )2f u u
θθ θ θπ
⎡ ⎤= + −⎢ ⎥⎣ ⎦  : 3-tanh-model. 
7. ( )4- tanh 0 1 2 32( , ) arctan ( )f u uθ θ θ θ θπ= + −  : 4-tanh-model. 
8. 1 1 lnexp 0 0( , ) uf u u eθ θθ θ ϑ= =  : Exponential time-power model.   
9. 2 ln2exp 0 1( , ) uf u e θθ θ θ −= −  : Reparametrized Exponential 
time-power model.  
10. ( )30 0 1 2( , ) ( ) exp ( )Wf u u θθ θ θ θ θ= − − −  : Reconstructed Weibull model.  
11. 1 2 ( )0( , ) 1
g u
GLf u e
θ θθ θ +⎡ ⎤= +⎣ ⎦  : Generalized Logistic model 
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We evaluate for various models parameters Fisher’s Information Matrix for one 
observation is 2( ) ( ) ( )Ti f fθ σ −= ∇ ∇ . Indeed: 
a. For the Gompetz model, 
12
0
2 22
0 0
1 ln
( )
ln (ln )
uui
u u
θ θθ θ θσ
⎡ ⎤= ⎢ ⎥⎣ ⎦
. 
b. For the reparametrized Exponential time-power model, 
2 2
2 2 2
2 2 2
1
2 22
1
2 22
1 1 1
1
( )
( )
u u
u u u
u u u
e ue
i e e ue
ue ue u e
θ θ
θ θ θ
θ θ θ
θ
θ σ θ
θ θ θ
−
− −−
− − −
⎡ ⎤−⎢ ⎥= − −⎢ ⎥⎢ ⎥−⎣ ⎦
. 
c. For the reconstructed Weibull model, the partial derivatives are: 
3
2( )
0
( , ) 1 uWf u e
θθθθ
−∂ = −∂ , 
3
2( )
1
( , ) uWf u e
θθθθ
−∂ = −∂ , 
 3 3 32 1( )0 1 2 2
2
( , ) ( )  ( >0)uWf u e u
θ θ θθθ θ θ θ θθ
−−∂ = −∂ ,  
3
32( )
0 1 2 2 2
3
( , ) ( ) ( ) ln( ) ( 0)uWf u e u u u
θ θθθ θ θ θ θ θθ
−∂ = − >∂ . 
Therefore, [ ] 4
1
2
,
( ) kl k li iθ σ − ∈= ` , where 
3
2
2
( )
11 1
ui e
θθ−⎡ ⎤= −⎣ ⎦ , 
3
22( )
22
ui e
θθ−= ,  
3
32
2
( )0 1
33 2
2
( )ui e u
θ θθθ θ θθ
−⎡ ⎤−= ⎢ ⎥⎣ ⎦
, 3 32 22( )2 244 0 1 2 2( ) (ln ) ( )
ui u e u
θ θθθ θ θ θ−= − , 
3 3
2 2( ) ( )
12 21 1
u ui i e e
θ θθ θ− −⎡ ⎤= = − −⎣ ⎦ ,  
3 3
32 2( ) ( )0 1
13 31 2
2
1 ( )u ui i e e u
θ θ θθ θθ θ θθ
− −−⎡ ⎤= = −⎣ ⎦ , 
3 3
32 2( ) ( )
14 41 0 1 2 21 ( ) ln( ) ( )
u ui i e u e u
θ θ θθ θθ θ θ θ− −⎡ ⎤= = − −⎣ ⎦ , 
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3 3
32 2( ) ( )0 1
23 32 2
2
( )u ui i e e u
θ θ θθ θθ θ θθ
− −−= = − , 
3 3
32 2( ) ( )
24 42 0 1 2 2( ) ln( ) ( )
u ui i e u e u
θ θ θθ θθ θ θ θ− −= = − − , 
3
32
2
22( )0 1
34 43 2 2
2
( ) ln( ) ( )ui i u e u
θ θθθ θ θ θθ
−−= = . 
d. For the Generalized Logistic model, we have the following cases: 
Case (i): 2 31 2 3( )g u u u uθ θ θ= + + , and therefore  
2 3
1 2 3 4
0( , )
1
GL u u u
f u
eθ θ θ θ
θθ + + += + . 
For this case the partial derivatives are: 
2 3
1 2 3 4
0
1( , )
1
GL
u u u
f u
eθ θ θ θ
θθ + + +
∂ =∂ + , 
( )
2 3
1 2 3 4
2 3
1 2 3 4
0
2
1
( , )
1
u u u
GL
u u u
f eu
e
θ θ θ θ
θ θ θ θ
θθθ
+ + +
+ + +
∂ = −∂ +
,  
( )
2 3
1 2 3 4
2 3
1 2 3 4
0
2
2
( , )
1
u u u
GL
u u u
f ueu
e
θ θ θ θ
θ θ θ θ
θθθ
+ + +
+ + +
∂ = −∂ +
,  
( )
2 3
1 2 3 4
2 3
1 2 3 4
2
0
2
3
( , )
1
u u u
GL
u u u
f u eu
e
θ θ θ θ
θ θ θ θ
θθθ
+ + +
+ + +
∂ = −∂ +
,  
( )
2 3
1 2 3 4
2 3
1 2 3 4
3
0
2
4
( , )
1
u u u
GL
u u u
f u eu
e
θ θ θ θ
θ θ θ θ
θθθ
+ + +
+ + +
∂ = −∂ +
. 
Case (ii): 
3
3
1( ) ug u
θ
θ
−= , and therefore  
3
1 2
3
0
1
( , )
1
GL u
f u
e
θ
θ θ θ
θθ −+= +
. 
For this case the partial derivatives are: 
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3
1 2
3
1
0
1( , )
1
GL
u
f u
e
θ
θ θ θ
θθ −+
∂ =∂ +
, 
3
1 2
3
3
1 2
3
1
0
2
11
( , )
1
u
GL
u
f eu
e
θ
θ
θ θ θ
θ θ θ
θθθ
−+
−+
∂ = −∂ ⎛ ⎞⎜ ⎟+⎜ ⎟⎝ ⎠
, 
3
1 2
3 3
3
1 2
3
1
0
2
12
3
( 1)( , )
1
u
GL
u
f u eu
e
θ
θ
θ θθ θ
θ θ θ
θθθ
θ
−+
−+
∂ −= −∂ ⎛ ⎞⎜ ⎟+⎜ ⎟⎝ ⎠
, 
[ ]
3
1 2
3 3 3
3
1 2
3
1
1
0 2 3
2
13
2
3
( 1) (ln ) 1
( , )
1
u
GL
u
u u u ef u
e
θ
θ
θ θθ θ θ
θ θ θ
θ θ θθθ
θ
−+−
−+
− −∂ = −∂ ⎛ ⎞⎜ ⎟+⎜ ⎟⎝ ⎠
. 
Then we can evaluate the Fisher’s Information matrix ( )i θ . The information matrix 
of this model does not depend on the linear added term. That is, in principle, for the 
model ( , )g u θ  and 0( , ) ( , )f u g uθ θ θ= +  the estimated Fisher’s information matrix 
needs prior information of the parameters involved in ( , )g u θ , not for 0θ . The 
estimation of 2σ , 2s  is also needed so that to have an estimate  
2
ˆ
ˆˆ( ) ( ) ( ) |Ti f f s θ θθ − == ∇ ∇ . 
Conclusions 
There is a theoretical background to cover the performance of any Bioassay, so for a 
cancer one. Not only to impose the appropriate formulation to group the data set in 
Tables as far as descriptive statistics concern. Interest was also on how to use the 
appropriate non-linear usually model. This model can be either a binary response one, 
or any other non-linear model in the continuous case. We provided a critical view of 
this analysis and, we believe, we offer this appropriate background to 
experimentalists. So the link between statistical/mathematical model and a cancer 
bioassay to be better bridged. 
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 Appendix A 
• More about Michaelis-Menten model 
The biochemical model for a simple enzyme-substate reaction, derivate by Michaelis-
Menten has various form extension. 
I. Consider the reaction scheme  
1 3
2
        k k
k
E S ES E P+ ⎯⎯→ +ZZZXYZZ ,  (A1.1) 
with E : enzyme, S : its substrate, P : product of the reaction, 321 ,, kkk : rate 
constants. In the steady state concentration, denoted by [], of ES  is constant so that  
1 2 3[ ][ ] ( )[ ]k E S k k ES= + .  (A1.2) 
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If  0E  is the total concentration of enzyme present, actually independent of time, then 
0 [ ] [ ]E E ES= + .  (A1.3) 
So (2) from (3) becomes  
1 0
1 0 1 2 3
1 2 3
[ ][ ] ( [ ] )[ ]    [ ]
[ ]
k S Ek s E k S k k ES ES
k S k k
= + + ⇒ = + + .  (A1.4) 
Equation (4) presents a rectangular hyperbola in ][S , and provides the concentration 
of substrate molecules that are combined with enzyme molecules. The older than MM 
known as Langmuir´s absorption isotherm was of the same form. It was referring to 
the absorption of gas molecules on the solid surfaces. 
Let as demote by ν  the speed of the steady-state reaction 3[ ]k ESν = . Then from (4) 
we get  
1 3 0 max
1 2 3
[ ] [ ]:
[ ] [ ]
k k E S V S
k S k k K S
ν = =+ + + .  (A1.5) 
With  
03max EkV = , max
1
32 :: KK
k
kk
K M ==+= , (A1.5a) 
the MM constant maxMK K K≡ ≡  is the value of substrate concentration for the half-
maximal velocity, max 2V V= .  
The maxV  denote the maximum velocity of the reaction and is obtained when all the 
active sites on the enzyme molecules are occupied by substrate molecules. 
From (5) it is easy to see that the passes through the origin when [ ] 0S = . The slope is  
K
V
Sd
d
S
max
0][][
==ν .   
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Figure A.1. The Michelis-Menten model. 
Νοtice that, if we let [ ]x S= , 
2
max
)( xK
KV
dx
d
M
M
+=
ν
,  
2
max
2 3
2
( )
M
M
V Kd
dx K x
ν = − + .   (A1.7) 
The rectangular hyperbola or MM needs two parameters to be specified: those which 
define the asymptotes or equivalently the parameters of the model. 
• Applications  of  Rectangular  Hyperbola (single substrate) 
• The specific growth rates of micro-organisms [Dean-Hinshelwood, pg. 80-81] 
• The respiration rate of mature leaves [Yemm, pg. 275] 
• The respiration in potatoes [Barker] 
It is interest to notice that leaf photosynthesis, among other physiological problems, 
are considered as non-rectangular hyperbolic responses with single substrate, while 
rectangular hyperbolas for two substrates of the form 
2132211
21
1 xxCxCxC
xkx
+++=ν .  (A1.8) 
maxVV =  
K  K2  K3  K−  
max2
1V−  
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The equation (5) describes two-substrate enzyme kinetics under certain conditions; 
see Dixon-Webb, pg. 100. 
So (8) is a more general form of (5) or any rectangular hyperbola of the form  
xb
ax
+ , with ba, constants. 
II. Now, modify the MM in the form  
22         E X EX E product+ ⎯⎯→ +ZZXYZZ , 
where :E enzyme, :X substrate. 
In such a case molecules of X  can combine with E  only two at the time. It can be 
shown that the utilization rate V  of substrate X  is given by  
22
2
XK
VxU += .  (A1.9) 
Sometimes a factor X  is above a critical value cK . 
The response can be derived from molecular models and it can be of the form 
nn
c
n
XK
VxU +=  ,  (A1.10) 
with cK  the threshold, U  the response, X  the density concentration level of some 
substance :cK value of X  for half-maximal response, :n usually positive integer and 
V  a constant. 
n
c
n
c
KX
KX
V
U
)(1
)(
+= .  (A1.11) 
Another model can be  
n
cKXV
U
)(1
1
+= .   (A1.11a) 
Model (A1.11) is of the same form of the Morgan-Marcer-Flodin (MMF) family of 
models 
1
1
0 2 3
3
( , )MMF
x
f u
x
θ
θ
θ θ θθ θ
+= + ,  (A1.11b) 
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see Seber and Wild (1989, pg. 342) for details. 
• MM process in PARALLEL 
The overall behavior of two MM transport process working independently in parallel 
process. The total flux density M is assumed to be 
1 2
1 2
1 2
[ ] [ ]MM CMM CMM
[ ] [ ]
V S V S
K S K S
= + = ++ + , 
with CMM1 contributed  MM1 , CMM2 contributed  MM2 , 1 2 1 2, , ,V V K K  constants. 
[ ]
d
d S
 M= 1 1 2 22 2
1 2( [ ]) ( [ ])
V K V K
K S K S
++ + , 
2
2[ ]
d
d S
 M = 1 1 2 23 3
1 2
2 2
( [ ]) ( [ ])
V K V K
K S K S
− −+ + , 
][Sd
d
 M [ ] 0S = = 1 2
1 2
[ ]
V V M SK K
+ →∞ ≈ 1 2V V+ . 
• MM processes in SERIES 
31
2 4
        kk
k k
E S ES E I+ +ZZZX ZZZXYZZ YZZ ,  (A1.13) 
where , ,E S I  are enzymes, 
MM= 0 1 3 1 3
2 3 1 4
( [ ] [ ])
[ ] [ ]
E k k S k k I
k k k S k I
−
+ + + , 
where 0E : total concentration of enzyme present. 
• Photosynthetic Response Light and CO2 
0 0
max
0 0
,P C P uP u C
P C P u
η ηη= = =+ + . 
• Leaf Response to light flux density tI : 
max
max
t
d
t
aI PP R
aI Pη
= −+ . 
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Appendix B 
The figures presented here are evaluated with parameters equal to 1. However, in any 
of the following models, the reader can examine how a model behaves by changing 
the appropriate iθ ’s and then can observe corresponding change in the related figure 
(in the MS Word document of this paper double-click on iθ ’s in order to change 
them, and then right-click on the related figure below and choose “update link” in 
order to update the figure. Thus, the reader needs to have the MS Word document of 
this paper and the additional Graph.xls file –provided by the authors upon request– in 
the same folder). 
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Figure B.1. Gompetz model. 
• 30 1 2( , ) exp( )Jf u uθθ θ θ θ= + . 
 
 
 
 
 
 
 
 
 
Figure B.2. Janoscheck model. 
θ0 1,00
θ1 1,00
θ2 1,00
θ0 1,00
θ1 1,00
θ2 1,00
θ3 1,00
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Figure B.3. Logistic model. 
• 30 1 2( , ) [ exp( )]Bf u uθ θ θ θ= + . 
 
 
 
 
 
 
 
 
 
Figure B.4. Bertalanffy model. 
θ0 1,00
θ1 1,00
θ2 1,00
θ0 1
θ1 1
θ2 1
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Figure B.5. Comparison of Janoscheck and Bertalanffy models. 
• ( )tanh 0 1 2 3( , ) tanh ( )f u uθ θ θ θ θ= + − . 
 
 
 
 
 
 
 
 
 
Figure B.6. tanh-model. 
θ0 1,00
θ1 1,00
θ2 1,00
θ3 1,00
θ 0 1 , 0 0
θ 1 1 , 0 0
θ 2 1 , 0 0
θ 3 1 , 0 0
28 ΙCCRA3 Proceedings 
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
-5 -4 -3 -2 -1 0 1 2 3 4 5
f3-tanh
u
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
2
-5 -4 -3 -2 -1 0 1 2 3 4 5
f4-tanh
u
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⎡ ⎤= + −⎢ ⎥⎣ ⎦ . 
 
 
 
 
 
 
 
 
 
Figure B.7. 3-tanh-model. 
• ( )4- tanh 0 1 2 32( , ) arctan ( )f u uθ θ θ θ θπ= + − . 
 
 
 
 
 
 
 
 
 
Figure B.8. 4-tanh-model. 
θ0 1
θ1 1
θ2 1
θ3 1
θ0 1
θ1 1
θ2 1
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Figure B.9. Comparison of tanh-,3-tanh- and 4-tanh-models. 
• 1 1 lnexp 0 0( , ) uf u u eθ θθ θ ϑ= = , 2 ln2exp 0 1( , ) uf u e θθ θ θ −= − . 
 
 
 
 
 
 
 
 
 
 
Figure B.10. Comparison of exponential and reparametrized exponential time-power models. 
θ0 1,00
θ1 0,50
θ2 1,00
θ3 1,00
θ0 1,00
θ1 1,00
θ2 1,00
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Figure B.11. Reconstructed Weibull model. 
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Figure B.12. Generalized Logistic models (cases i and ii). 
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